Mymetics Corp (MYMX)

[TheHungryHippo]

YOU HAVE UNLOCKED THE SANOFI DOUBLE DOUBLE SECRET.

IN FU**ING CREDIBLE FIND MY FRIEND. AND LET ME TELL YOU WHY.

Now that you have shown this patent, we can clearly see that Mymetics is responsible for the formulation of the "WINNING" combination FORMULATION that IMMUGENE have chose to move forward with to defeat certain cancerous tumors. BUT IT GETS DEEPER THAN THAT.

Patent that shows MYMX is manufacturing the combination using Bachem's P647 Peptide, combined with the monoxide CRM197 from Merck!

https://www.google.com/patents/US20170119867



Her-2/neu for a vaccine that was tested in a phase-I clinical trial

So here they describe the purpose of the Clinical Trial:

The aim of the current study was therefore to compare the immunogenicity of the selected hybrid peptide in mice,

1) when coupled to CRM compared to virosomes to select a potent carrier for the hybrid peptide vaccine, and

2) when administered together with Montanide (a Th1 driving adjuvant, with capacity to induce both antibody and cellular responses) [18]

or Alum (a Th2 driving adjuvant) [19] to select an adjuvant which gives more potent immune responses with anti-tumor effects.

Our results show that the peptide conjugated to CRM promotes induction of antibody responses, and in addition to humoral responses also cellular responses are induced at significantly higher levels with lower amounts of the peptide conjugate when administered together with Montanide in contrast to Alum.

In the immunization experiment-I both hybrid peptides were coupled to either virosomes or to CRM (Mymetics, The Netherlands), and in experiment-II the hybrid peptide was only coupled to CRM (piCHEM, Austria).

The hybrid peptides P467 and P647, conjugated to either CRM or virosomes, were examined with two different adjuvants, namely Alum (Aluminium hydroxide; Brenntag, Denmark/ Serva, Germany), or Montanide ISA-51-VG (Seppic, France) which is a water-in-oil emulsion.

These results indicated that administration of only 10 µg of the P467-CRM conjugate with Montanide can induce significantly higher Th1-polarized antibody responses than the higher dose (50 µg) of the peptide-conjugate administered with Alum.

Our results also clearly showed that already with the lowest tested concentration (10 µg per dose) of the P467-CRM conjugate plus Montanide, the antibody titers were higher than compared with the highest tested concentration (50 µg per dose) of the formulation containing Alum, and indicated the superiority of Montanide- over Alum-containing formulation in eliciting IgG and IgG1 responses at any examined dose. The fact that already with low concentrations of the hybrid plus Montanide high immune responses are induced, is beneficial in terms of the manufacturing process of the formulation, and further signifies the advantage of Montanide in our CRM-conjugate hybrid peptide formulation. In addition, our results showed that even six months after the last immunization the serum IgG responses were higher in the groups of mice administered with Montanide than with Alum

When conjugated to CRM, our selected hybrid peptide induces considerably higher and more rapid immune responses compared to the virosome-conjugated peptides, elicits long-lasting antibody responses and exhibits antitumor activity. Also administration of the CRM conjugate with Montanide, compared to Alum, induces not only CD4 Th1-driven responses but also IFN?-producing CD8 T cells already in the lowest concentration of the dose. Taken together, these results suggest the potential of our novel formulation containing CRM-P467 plus Montanide as a vaccine against Her-2/neu with polyclonal anti-tumor effect. The formulation P467-CRM-Montanide has recently been examined in a toxicology study and shown no signs of toxicity or inflammation when evaluated in dogs and rats (data not shown). A dose-escalating study, starting with 10 µg of the formulation, is being planned to be evaluated in a phase-Ib/II clinical trial enrolling Her-2/neu overexpressing cancer patients.


ITS A "HYBRID" MEANING IT CONTAINS BOTH, THE VIROSOME AND THE MONTANIDE.


AND NOW THEY ARE MOVING INTO PHASE 2.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3098-7


BUT IT GETS DEEPER THAN THAT.

YOU SEE. MYMETICS HOLDS THE PATENT FOR THIS FORMULATION.

WO/2004/106366 (UK39) Methods for synthetizing conformationally constrained peptides, peptidomimetics and use of such peptidomimetics as synthetic vaccines Mymetics Corp. Expiration date: June 1, 2024

Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines

Preparation of mimetic-loaded virosomes

For the preparation of PE-mimetic-IRIV, a solution of 4 mg purified Influenza A/Singapore hemagglutinin is centrifuged for 30 min at 100,000g and the pellet is dissolved in 1.33 ml of PBS containing lOOmM OEG (PBS-OEG) . 32 mg phosphatidylcholine (Lipoid, Ludwigshafen, Germany) , 6 mg phosphatidylethanolamine and the PE-mimetics are dissolved in a total volume of 2.66 ml PBS-OEG. The phospholipids and the hemagglutinin solution are mixed and sonicated for 1 min. This solution is then centrifuged for 1 hour at 100,000g and the supernatant is sterile filtered (0.22 µm) . Virosomes are then formed by detergent removal using BioRad SM BioBeads (BioRad, Glattbrugg, Switzerland) .

for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to compositions containing the same.

http://russianpatents.com/patent/244/2441647.html


SO WHATS THAT GOT TO DO WITH SANOFI YOU ASK?

ITS COMPATIBLE WITH THESE STRAINS OF INFLUENZA!!!!!!



WHAT IS HEMAGGLUTININ?


"Biologically active "hemagglutinin" makes a significant contribution to immunological properties, because it maintains the ability of viruses to merge."

HEMAGGLUTININ

Multiple different hemagglutinin (HA) protein antigens have been reproducibly manufactured at the 650L scale by Protein Sciences Corporation (PSC) based on an insect cell culture with baculovirus infection. Signi cantly, these HA protein antigens were produced by the same Universal Manufacturing process as described in the biological license application (BLA) for the 1st recombinant influenza vaccine approved by the FDA (Flublok®)

SO YOU ASK YOURSELF.. WHY DOES SANOFI NEED MYMETICS EVEN MORE?

BECAUSE. AS PROVED WITH THE IMUGENE TRIAL. THE HYBRID VIROSOME VACCINES ARE CAPABLE OF INCREASING IMMUNOGENICITY AND! WE KNOW FROM THE MACVIVA PROJECT- THAT IT MAKES IT POSSIBLE TO INCREASE THE LONGEVITY OF STORAGE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

MYMETICS CAN MAKE VIROSOMES WITH HA PROTEINS.

NOW LOOK AT THIS!

The recombinant hemagglutinin (rHA)-based influenza vaccine Flublok® has recently been approved in the United States as an alternative to the traditional egg-derived flu vaccines. Flublok is a purified vaccine with a hemagglutinin content that is threefold higher than standard inactivated influenza vaccines. When rHA derived from an H3N2 influenza virus was expressed, purified, and stored for 1 month, a rapid loss of in vitro potency (50%) was observed as measured by the single radial immunodiffusion (SRID) assay.

http://www.proteinsciences.com/Abstract/files/assets/common/downloads/page0010.pdf

PROTEIN SCIENCES HOLDS INCREDIBLE TECHNOLOGY, BUT THE COLD-CHAIN STORAGE PROCESS INHIBITS THEM FROM DISTRIBUTING ALL STRAINS OF HA BASED VACCINES EFFECTIVELY!

THIS IS WHY SANOFI NEEDS MYMETICS. THIS IS WHY WE FIT ALONG WITH THE PROTEIN SCIENCES ACQUISITION.

IN THE EVENT OF A WORLDWIDE PANDEMIC.

AN INDEPENDENT COLD-CHAIN STORAGE MANUFACTURING PROCESS WILL BE NEEDED TO EFFECTIVELY DISTRIBUTE RECOMBINANT VACCINES THROUGHOUT THE WORLD.

$MYMX